We support cell and gene therapy clients across CAR-T, TCR-based therapies, gene editing platforms, and viral vector development. Our network includes experts in autologous and allogeneic manufacturing, process development, and analytical sciences.

Our RNA therapeutics business connects clients with talent across mRNA, siRNA, antisense oligonucleotides, and lipid nanoparticle delivery systems. We support both platform development and clinical-stage programmes.

We work with clients developing CRISPR, base editing, and prime editing technologies, connecting them with scientists and engineers driving next-generation precision medicine platforms.

In oncology, we support biotechs advancing novel biologics, immuno-oncology therapies, ADCs, and targeted therapies, connecting clients with translational, clinical, and CMC talent driving programmes from bench to bedside.

We connect immunology-focused biotechs with specialists across autoimmune disease, inflammatory conditions, and novel biologics, supporting discovery through clinical development.

We support biotechs developing gene therapies, novel biologics, and cell-based approaches for retinal and ocular diseases, connecting clients with translational and clinical talent advancing next-generation vision-preserving treatments.

Our neuroscience network covers biotechs developing therapies for neurodegenerative and neurological conditions, including gene therapies, biologics, and novel small molecule approaches.

We support rare disease biotechs with talent across gene therapy, enzyme replacement, and orphan drug development, understanding the unique regulatory pathways (e.g. Orphan Drug Designation, accelerated approval) these programmes require.

We connect clients with specialists in vaccine development, monoclonal antibodies, and antiviral therapeutics, supporting biotechs responding to emerging and established infectious disease threats.

Our bioinformatics network supports biotechs leveraging AI/ML, genomics, and computational platforms to accelerate target identification, drug discovery, and biomarker development.

We support clients working in synthetic biology, bioprinting, and tissue engineering, connecting them with talent building next-generation platforms in regenerative medicine.

Our metabolic disease network covers biotechs developing GLP-1 and next-generation peptide therapies, connecting clients with talent driving one of the fastest-growing pipeline categories in the industry.

We connect cardiovascular-focused biotechs with specialists in novel biologics, gene therapies, and precision cardiology approaches, an area of particular growth in emerging biotech markets.